Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Amino Acids ; 53(9): 1415-1430, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34410507

ABSTRACT

Oral mucositis is an inflammation of the oral mucosa mainly resulting from the cytotoxic effect of 5-fluorouracil (5-FU). The literature shows anti-inflammatory action of L-cysteine (L-cys) involving hydrogen sulfide (H2S). In view of these properties, we investigate the effect of L-cys in oral mucositis induced by 5-FU in hamsters. The animals were divided into the following groups: saline 0.9%, mechanical trauma, 5-FU 60-40 mg/kg, L-cys 10/40 mg and NaHS 27 µg/kg. 5-FU was administered on days 1st to 2nd; 4th day excoriations were made on the mucosa; 5th-6th received L-cys and NaHS. For data analysis, histological analyses, mast cell count, inflammatory and antioxidants markers, and immunohistochemistry (cyclooxygenase-2(COX-2)/inducible nitric oxide synthase (iNOs)/H2S) were performed. Results showed that L-cys decreased levels of inflammatory markers, mast cells, levels of COX-2, iNOS and increased levels of antioxidants markers and H2S when compared to the group 5-FU (p < 0.005). It is suggested that L-cys increases the H2S production with anti-inflammatory action in the 5-FU lesion.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Cysteine/pharmacology , Fluorouracil/toxicity , Hydrogen Sulfide/metabolism , Inflammation/prevention & control , Stomatitis/drug therapy , Animals , Antimetabolites, Antineoplastic/toxicity , Antioxidants/pharmacology , Cricetinae , Cyclooxygenase 2/metabolism , Inflammation/etiology , Inflammation/metabolism , Inflammation/pathology , Male , Nitric Oxide Synthase Type II/metabolism , Stomatitis/chemically induced , Stomatitis/immunology , Stomatitis/pathology
2.
Inflammation ; 44(2): 617-632, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33128666

ABSTRACT

The aim of this study was to evaluate the effects of glutamine supplementation or exercise on gastric emptying and intestinal inflammation in rats with ulcerative colitis (UC). Strength exercise consisted of jump training 4 × 10 repetitions/5 days a week/8 weeks with progressive overload. Endurance exercise consisted of swimming without overload for a period of 1 h a day/5 days a week/8 weeks. Another group (sedentary) of animals was supplemented with L-glutamine (1 g/kg of body weight) orally for 8 weeks before induction of UC. Colitis was induced by intra-colonic administration of 1 mL of 4% acetic acid. We assessed gastric emptying, macroscopic and microscopic scoring, oxidative stress markers, and IL-1ß, IL-6, and (TNF-α) levels. The UC significantly increased (p < 0.05) the gastric emptying compared with the saline control group. We observed a significantly decrease (p < 0.05) in body weight gain in UC rats compared with the control groups. Both exercise interventions and L-glutamine supplementation significantly prevented (p < 0.05) weight loss compared with the UC group. Strength and endurance exercises significantly prevented (p < 0.05) the increase of microscopic scores and oxidative stress (p < 0.05). L-glutamine supplementation in UC rats prevented hemorrhagic damage and improved oxidative stress markers (p < 0.05). Strength and endurance exercises and glutamine decreased the concentrations of inflammatory cytokines IL-1ß, IL-6, and TNF-α compared with the UC group (p < 0.05). Strength and endurance exercises and L-glutamine supplementation prevented intestinal inflammation and improved cytokines and oxidative stress levels without altering gastric dysmotility in rats with UC.


Subject(s)
Colitis, Ulcerative/therapy , Gastrointestinal Agents/therapeutic use , Gastrointestinal Motility/drug effects , Glutamine/therapeutic use , Oxidative Stress/drug effects , Physical Conditioning, Animal/methods , Administration, Oral , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Biomarkers/metabolism , Colitis, Ulcerative/metabolism , Colitis, Ulcerative/pathology , Colitis, Ulcerative/physiopathology , Colon/drug effects , Colon/metabolism , Colon/pathology , Combined Modality Therapy , Cytokines/metabolism , Dietary Supplements , Drug Administration Schedule , Gastrointestinal Agents/pharmacology , Gastrointestinal Motility/physiology , Glutamine/pharmacology , Male , Oxidative Stress/physiology , Rats , Rats, Wistar , Treatment Outcome , Weight Loss/drug effects , Weight Loss/physiology
3.
Biomed Pharmacother ; 110: 631-640, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30540974

ABSTRACT

Diarrhea is one of the leading causes of infant death in the world accounting for high child mortality rate. It is also present in different pathophysiologies related to several etiological agents. The aim of this study is to investigate the antidiarrheal effect of α -Terpineol (α-TPN) in different diarrhea models in rodents. The antidiarrheal effect of α-TPN in the treatment of acute diarrhea and enteropooling induced by castor oil or PGE2 in Swiss mice pretreated orally with saline (NaCl 0.9%), Loperamide (5 mg/kg) and α-TPN (6.25, 12.5, 25 and 50 mg/kg) was analyzed. Additionally, parameters of severity, total weight of faeces and post-treatment for 4 h were evaluated. Modulation of the opioid and cholinergic pathways was performed and intestinal transit model using activated charcoal as marker was also used. The effect of α-TPN on secretory diarrhea was investigated using the model of fluid secretion in intestinal loops isolated from cholera toxin-treated mice. α-TPN showed antidiarrheal effect (*p < 0.05), reducing the total stool amount (*55%, *48%, *44%, *24%) and diarrheal (*47%, *66%; *56%, 10%) respectively for the doses tested. All doses investigated in the enteropooling test presented significant changes (*46%, *78%, *66%, *41% respectively) in relation to the control. α-TPN through the muscarinic pathway reduced the gastrointestinal transit (*31%), besides inhibiting PGE2-induced diarrhea (*39%). α-TPN also reduced fluid formation and loss of Cl- ions, by interacting directly with GM1 receptors and cholera toxin, thus increasing the uptake of intestinal fluids. The results suggest an anti-diarrheal activity of α-TPN due to its anticholinergic action, ability to block PGE2 and GM1 receptors and interaction with cholera toxin in secretory diarrhea, making it a promising candidate drug for the treatment of diarrheal diseases.


Subject(s)
Antidiarrheals/therapeutic use , Cyclohexenes/therapeutic use , Diarrhea/drug therapy , Gastrointestinal Motility/drug effects , Monoterpenes/therapeutic use , Animals , Antidiarrheals/pharmacology , Castor Oil/toxicity , Cyclohexane Monoterpenes , Cyclohexenes/pharmacology , Diarrhea/chemically induced , Diarrhea/physiopathology , Dose-Response Relationship, Drug , Female , Gastrointestinal Motility/physiology , Male , Mice , Monoterpenes/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...